Tiacci E, De Carolis L, Simonetti E, et al. - Researchers conducted a phase 2, single-center, academic trial to determine the safety as well as efficacy of vemurafenib (960 mg, given twice daily for 8 weeks) plus concurrent and sequential rituximab (375 mg per square meter of body-surface area, given for 8 doses over a period of 18 weeks) in patients suffering from refractory or relapsed hairy-cell leukemia (HCL). A complete response at the completion of planned treatment was the primary endpoint. Findings of this small study revealed that a durable complete response in most patients with refractory or relapsed HCL was conferred by a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab.